U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

School of Health and Related Research (ScHARR), University of Sheffield. Clinical Guidelines for the Classification and Care of Women at Risk of Familial Breast Cancer in Primary, Secondary and Tertiary Care [Internet]. Sheffield (UK): University of Sheffield; 2004 May. (NICE Clinical Guidelines, No. 14.)

Cover
  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Clinical Guidelines for the Classification and Care of Women at Risk of Familial Breast Cancer in Primary, Secondary and Tertiary Care

Clinical Guidelines for the Classification and Care of Women at Risk of Familial Breast Cancer in Primary, Secondary and Tertiary Care [Internet].

Show details

12. References

  • Aitken LS, West SG, Woodward CK, et al. Increasing screening mammography in asymptomatic women: evaluation of a second generation theory-based program. Health Psychology. 1994;13:122–29. [PubMed: 7889908]
  • Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A. Evaluation of Breast Cancer Risk Assessment Packages in the Family History Evaluation and Screening Programme. J Med Genet. 2003 in press. [PMC free article: PMC1735317] [PubMed: 14627668]
  • Andermann AA, Austoker J, Watson EK, et al. Development and evaluation of a general information leaflet for women with a family history of breast cancer. Journal of Cancer Education. 2002;17:155–60. [PubMed: 12243221]
  • Andermann A, Narod SA. Genetic counselling for familial breast and ovarian cancer in Ontario. Journal of Medical Genetics. 2002;39:695–696. [PMC free article: PMC1735233] [PubMed: 12205116]
  • Andermann AA, Watson EK, Lucassen AM, Austoker J. The Opinions, Expectations and Experiences of Women with a Family History of Breast Cancer Who Consult Their GP and Are Referred to Secondary Care. Community Genet. 2001;4(4):239–43. [PubMed: 12107353]
  • Anderson DE, et al. Risk of familial breast cancer. Cancer. 1985;56:937–48. [PubMed: 4005803]
  • Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with mutations in BRCA1 or BRCA2 detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30. [PMC free article: PMC1180265] [PubMed: 12677558]
  • Arnold N, et al. A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers. Hum Mutat. 1999;14:333–9. [PubMed: 10502781]
  • Band PR, et al. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet. 2002;360:1044–1049. [PubMed: 12383984]
  • Bastani R, Maxwell A, Bradford C, et al. Tailored risk notification for women with a family history of breast cancer. Preventive Medicine. 1999;29:355–364. [PubMed: 10564627]
  • Baxter N, et al. Preventative Health Care, 2001 Update: Should Women Be Routinely Taught Breast Self-Examination to Screen for Breast Cancer. CMAJ. 2001;164(13) [PMC free article: PMC81191] [PubMed: 11450279]
  • Bebbington Hatcher M, Fallowfield L. A qualitative study looking at the psychosocial implications of bilateral prophylactic mastectomy. The Breast. 2003;12:1–9. [PubMed: 14659349]
  • Bernhardt B, et al. Toward a model informed consent process for BRCA1 testing: a qualitative assessment of women’s attitudes. Journal of Genetic Counseling. 1997;6:207–22. [PubMed: 11656642]
  • Bernier MO, et al. Breastfeeding and risk of breast cancer: a meta-analysis of published studies. Human Reproduction Update. 2000;6:374–86. [PubMed: 10972524]
  • Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. Journal of the National Cancer Institute. 1997;89:227–38. (see comments) [PubMed: 9017003]
  • Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. Journal of the National Cancer Institute. 1997;89:227–38. (see comments) [PubMed: 9017003]
  • Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. Journal of the National Cancer Institute. 1994;86:620–5. (see comments) [PubMed: 8003106]
  • Borgen PI, Hill ADK, Tran KN, Van Zee KJ, Massie MJ, Payne D, et al. Patient regrets after bilateral prophylactic mastectomy. Annals of Surgical Oncology. 1998;5:603–6. [PubMed: 9831108]
  • Bottorff JL, Balneaves LG, Buxton J, Ratner PA, McCullum M, Chalmers K, et al. Falling through the cracks. Women’s experiences of ineligibility for genetic testing for risk of breast cancer. Canadian Family Physician. 2000;46:1449–56. [PMC free article: PMC2144854] [PubMed: 10925759]
  • Bottorff JL, et al. Communicating cancer risk information: the challenges of uncertainty. Patient Educ Couns. 1998;33:67–81. [PubMed: 9481350]
  • Bowles Biesecker B, Ishibe N, Hadley DW, Giambarresi TR, Kase RG, Lerman C, et al. Psychosocial Factors Predicting BRCA1/BRCA2 Testing Decisions in Members of Hereditary Breast and Ovarian Families. Am J Med Genet. 2000;93:257–63. [PubMed: 10946349]
  • Boyd NF, Lockwood GA, Martin LJ, Knight JA, Jong RA, Fishell E, et al. Mammographic densities and risk of breast cancer among subjects with a family history of this disease. Journal of the National Cancer Institute. 1999;91:1404–8. [PubMed: 10451446]
  • Brain K, Gray J, Norman P, Parsons E, Clarke A, Rogers C, Mansel R, Harper P. Why do women attend familial beast cancer clinics? Journal of Medical Genetics. 1999;37:197–202. [PMC free article: PMC1734549] [PubMed: 10699056]
  • Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. Journal of Clinical Oncology. 2001;19:924–30. (see comments) [PubMed: 11181654]
  • Brind J, et al. Induced abortion as an independent risk factor for breast cancer: a comprehensive review and meta-analysis. Journal of Epidemiology & Community Health. 1996;50:481–96. [PMC free article: PMC1060338] [PubMed: 8944853]
  • Broadstock M, Michie S, Gray J, Mackay J, Marteau TM. The psychological consequences of offering mutation searching in the family for those at risk of hereditary breast and ovarian cancer--a pilot study. Psycho-Oncology. 2000;9:537–48. [PubMed: 11180589]
  • Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: A qualitative review. Obstetrics-and-Gynecology. 2001;98:498–508. [PubMed: 11530137]
  • Butow PN, Lobb EA, Meiser B, Barratt A, Tucker KM. Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: a systematic review. Medical Journal of Australia. 2003;178:77–81. [PubMed: 12526728]
  • Byrne TJ, Reece MT, Adams LA, Hoffman DE, Lane MA, Cohn GM. A rapid immunoassay predicts BRCA 1 and BRCA 2 mutations in buccal cells. Oncol rep. 2000;7:1203–7. [PubMed: 11032914]
  • Cameron LD, Diefenbach MA. Responses to information about psychosocial consequences of genetic testing from breast cancer susceptibility: influences of cancer worry and risk perceptions. Journal of Health Psychology. 2001;6:47–59. [PubMed: 22049237]
  • Cappelli M, et al. Psychological and social predictors of decisions about genetic testing for breast cancer in high-risk women. Psychology, Health & Medicine. 2001;6:321–33.
  • Casilli F, Di Rocco ZC, Gad S, Tournier I, Stoppa-Lyonnet D, Frebourg T, et al. Rapid detection of novel BRCA 1 rearrangements in high-risk n=breast-ovarian cancer families using multiplex PCR of short flourescent lights. Hum Mutat. 2002;20:218–26. [PubMed: 12203994]
  • Chalmers K, Thomson K. Coming to terms with the risk of breast cancer: Perceptions of women with primary relatives with breast cancer. Qualitative Health Research. 1996;6:256–282.
  • Chart PL, Franssen E. Management of women at increased risk for breast cancer: preliminary results from a new program. CMAJ. 1997;157:1235–42. [PMC free article: PMC1228353] [PubMed: 9361645]
  • Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early onset breast cancer. Cancer. 1994;73:643–651. [PubMed: 8299086]
  • Cohen D, Barton G, Gray J. The cost of mutation searching on BRCA1 and BRCA2 for breast cancer predisposition. in submission.
  • Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. American Journal of Obstetrics & Gynecology. 1993;168:1473–80. [PubMed: 8498430]
  • Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease. Lancet. 2002;87:1234–45. [PMC free article: PMC2562507] [PubMed: 12439712]
  • Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96, 973 women without the disease. Lancet. 2002;360:187–95. [PubMed: 12133652]
  • Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. Lancet. 2001;358:1389–1399. [PubMed: 11705483]
  • Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet. 1997;350:1047–59. [PubMed: 10213546]
  • Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–27. [PubMed: 8656904]
  • Contant C, et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. European Journal of Surgical Oncology. 2002;28:627–32. [PubMed: 12359199]
  • Couch FJ, et al. Cigarette smoking increases risk for breast cancer in high-risk breast cancer families. Cancer Epidemiology, Biomarkers & Prevention. 2001;10:327–32. [PubMed: 11319172]
  • Croyle RT, Smith KR, Botkin JR, Baty B, Nash J. Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychology. 1997;16:63–72. [PubMed: 9028816]
  • Cull A, Anderson E, D C, Campbell S, Mackay J, Smyth E, Steel M. The impact of genetic counselling about breast cancer risk on women’s risk perceptions and levels of distress. British Journal of Cancer. 1999;79:501–508. [PMC free article: PMC2362435] [PubMed: 10027320]
  • Cull A, Miller H, Porterfield T, Mackay J, Anderson E, D C, Steel CM, Elton RA. The use of videotaped information in cancer genetic counselling: a randomized evaluation study. British Journal of Cancer. 1998;77:830–837. [PMC free article: PMC2149970] [PubMed: 9514066]
  • Curry SJ, Taplin SH, Anderman C, et al. A randomized trial of the impact of risk assessment and feedback on participation in mammography screening. Preventive Medicine. 1993;22:350–60. [PubMed: 8327418]
  • Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300. [PubMed: 12559863]
  • Day R, Ganz PA, Constantino JP, et al. Health related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project (P-1 Project). Journal of Clinical Oncology. 1999;17:2659–2669. [PubMed: 10561339]
  • de Bock GH, Vliet Vlieland TP, Hageman GC, Oosterwijk JC, Springer MP, Kievit J. The assessment of genetic risk of breast cancer: a set of GP guidelines. Family Practice. 1999;16:71–7. [PubMed: 10321400]
  • Delgado-Rodriguez M, et al. Oral contraceptives and breast cancer: a meta-analysis. Revue d'Epidemiologie et de Sante Publique. 1991;39:165–81. [PubMed: 1830968]
  • Department of Health. Interim advice to GPs on familial breast cancer. London: Department of Health; 2000.
  • Diefenbach MA, et al. Specific worry about breast cancer predicts mammography use in women at risk for breast and ovarian cancer. Health Psychology. 1999;18:532–6. [PubMed: 10519469]
  • Douglas FS, O'Dair LCO, Robinson M, Evans DGR, Lynch SA. The accuracy of diagnosis as reported by the proband in families with cancer: a retrospective study. J Med Genet. 1999;36:309–12. 1999. [PMC free article: PMC1734350] [PubMed: 10227399]
  • Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK. Human Reproduction. 2002;17:2209–2213. [PubMed: 12151460]
  • Drossaert CCH. Perceived risk, anxiety, mammogram uptake, and breast self-examination of women with a family history of breast cancer: the role of knowing to be at increased risk. Cancer Detection & Prevention. 1996;20:76–85. [PubMed: 8907207]
  • Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Archives of Internal Medicine. 1991;151:167–72. [PubMed: 1824675]
  • Durfy SJ, Bowen DJ, McTiernan A, Sporleder J, Burke W. Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiology, Biomarkers & Prevention. 1999;8:369–75. [PubMed: 10207642]
  • Eccles DM, Evans DG, Mackay J. Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). Journal of Medical Genetics. 2000;37:203–9. [PMC free article: PMC1734545] [PubMed: 10699057]
  • Edwards SM, Kote-Jarai Z, Meitz J, et al. Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators; British Association of Urological Surgeons Section of Oncology. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2002;72:1–12. Epub 2002 Dec 09. [PMC free article: PMC420008] [PubMed: 12474142]
  • Edwards SM, Kote-Jarai Z, Hamoudi R, Eeles RA. An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-flourescent mutation detection (F-MD). Hum Mutat. 2001;17:220–32. [PubMed: 11241844]
  • Eeles RA, Murday VA. The cancer family clinic. In: Eeles RA, et al., editors. Genetic Predisposition to Cancer. Oxford: Chapman & Hall Medical; 1996.
  • Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H. Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? European Journal of Cancer. 2000;36:1143–8. [PubMed: 10854948]
  • Eldar S, Meguid MM, Beatty JD. Cancer of the Breast After Prophylactic Subcutaneous Mastectomy. American Journal of Surgery. 1984;148:692–3. [PubMed: 6496863]
  • Elit L, Esplen MJ, Butler K, Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Familial Cancer. 2001;1:149–56. [PubMed: 14574171]
  • Elit L, Rosen B, Gael V, Michaughlin J, Fung MKF, Shime J, Narod S. Prophylactic oophorectomy in Ontario. Familial Cancer. 2001;1:143–8. [PubMed: 14574170]
  • Ellison RC, et al. Exploring the relation of alcohol consumption to risk of breast cancer. American Journal of Epidemiology. 2001;154:740–7. [PubMed: 11590087]
  • Emery J, Lucassen A, Murphy M. Common hereditary cancers and implications for primary care. Lancet. 2001;358:56–63. [PubMed: 11454400]
  • Emery J, Walton R, Coulson A, Glasspool D, Ziebland S, Fox J. Computer support for recording and interpreting family histories of breast and ovarian cancer in primary care (RAGs): qualitative evaluation with simulated patients. BMJ. 1999;319:32–6. [PMC free article: PMC28153] [PubMed: 10390458]
  • Emery J, Walton R, Murphy M, Austoker J, Yudkin P, Chapman C, et al. Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases. BMJ. 2000;321:28–32. (see comments) [PMC free article: PMC27423] [PubMed: 10875832]
  • Euhus DM, Smith KC, Robinson L, et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. Journal of the National Cancer Institute. 2002;94:844–51. [PubMed: 12048272]
  • Evans DG, Blair V, Greenhalgh R, Hopwood P, Howell A. The impact of genetic counselling on risk perception in women with a family history of breast cancer. Br J Cancer. 1994;70:934–938. [PMC free article: PMC2033538] [PubMed: 7947100]
  • Evans DG, Blair V, Greenhalgh R, Hopwood P, Howell A. The impact of genetic counselling on risk perception in women with a family history of breast cancer. British Journal of Cancer. 1994;70:934–938. [PMC free article: PMC2033538] [PubMed: 7947100]
  • Evans DGR, Lalloo F, Shenton A, Boggis C, Howell A. Uptake of screening and prevention in women at very high risk of breast cancer. The Lancet. 2001;358:889–90. [PubMed: 11567707]
  • Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, et al. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. Journal of Clinical Oncology. 2001;19:1885–92. [PubMed: 11283119]
  • Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. 1998;90:1371–88. (see comments) 1998. [PubMed: 9747868]
  • Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. 1998;90:1371–88. (see comments) 1998. [PubMed: 9747868]
  • Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, et al. The Breast Cancer Linkage Consortium: Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676–689. [PMC free article: PMC1376944] [PubMed: 9497246]
  • Foster C, Evans DGR, Eeles R, et al. Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. BR J CANCER. 2002;86:1209–16. [PMC free article: PMC2375339] [PubMed: 11953874]
  • Frolov A, Prowse AH, Vanderveer L, Bove B, Wu H, Godwin AK. DNA array-based method for detection of large rearrangements in the BRCA 1 gene. Genes Chromosomes Cancer. 2002;35:232–41. [PubMed: 12353265]
  • Frost MH, Schaid DJ, Sellers TA, Slezak JM, Arnold PG, Woods JE, et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. Jama-Journal of the American Medical Association. 2000;284:319–24. [PubMed: 10891963]
  • Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psycho-Oncology. 2001;10:231–41. [PubMed: 11351375]
  • Gad S, Aurias A, Puget N, Mairal A, Schurra C, Montagna M, et al. Colour bar coding the BRcA 1 gene on combed DNA: a useful strategy for detecting large gene arrangements. Genes Chromosomes Cancer. 2001;31:75–84. [PubMed: 11284038]
  • Gail MH, Brinton LA, Byar DP, Corle DK, Gree SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute. 1989;81:1879–86. [PubMed: 2593165]
  • Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. Journal of the National Cancer Institute. 1999;91:1829–46. [PubMed: 10547390]
  • Ganguly T, Dhulipala R, Godmilow L, Ganguly A. High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families. Human Genetics. 1998;102:549–56. [PubMed: 9654203]
  • Gayther SA, Harrington P, Russell PKG, Garkavtseva RF, Ponder BA. Rapid detection of regionally clustered germ-line BRCA 1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. Am J Hum Genet. 1996;58:451–6. [PMC free article: PMC1914578] [PubMed: 8644703]
  • Geisler JP, Hatterman-Zogg MA, Rathe JA, Lallas TA, Kirby P, Buller RE. Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand confrontation polymorphism analysis (SSCP). Hum Mutat. 2001;18:337–44. [PubMed: 11668617]
  • Gilbert FJ, Cordiner CM, Affleck IR, Hood DB, Mathieson D, Walker LG. Breast screening: the psychological sequelae of false-positive recall in women with and without a family history of breast cancer. European Journal of Cancer. 1998;34:2010–4. [PubMed: 10070302]
  • Gilpin CA, Carson N, Hunter AG. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clinical Genetics. 2000;58:299–308. [PubMed: 11076055]
  • Goffin J, Chappuis PO, Wong N, Foulkes WD, Stoutjesdijk MJ, Boetes C, et al. Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer (2). Journal of the National Cancer Institute. :1754–5. [PubMed: 11717339]
  • Goodnight JE, Quagliana JM, Morton DL. Failure of Subcutaneous Mastectomy to Prevent the Development of Breast-Cancer. Journal of Surgical Oncology. 1984;26:198–201. [PubMed: 6330460]
  • Grande GE, Hyland F, Walter FM, Kinmonth AL. Women's views of consultations about familial risk of breast cancer in primary care. Patient Educ Couns. 2002;48(3):275–82. [PubMed: 12477612]
  • Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI. Effect of prevention strategies on survival and quality adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. Journal of Clinical Oncology. 2002;20(10):2520–2529. [PubMed: 12011131]
  • Grann, et al. Prevention with Tamoxifen or other hormones versus prophylactic surgery in BRCA1/2- positive women: a decision analysis. The Cancer Journal. 2000;6:13–20. [PubMed: 10696733]
  • Grann, et al. Decision analysis of Tamoxifen for the prevention of invasive breast cancer. The Cancer Journal. 2000;6:169–178. [PubMed: 10882333]
  • Grann, et al. Benefits and costs of screening Askenazi Jewish Women for BRCA1 and BRCA2. Journal of Clinical Oncology. 1999;17(2):494–500. [PubMed: 10080590]
  • Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. Journal of Clinical Oncology. 1998;16:979–85. [PubMed: 9508180]
  • Green J, et al. Family communication and genetic counseling: the case of hereditary breast and ovarian cancer. Journal of Genetic Counseling. 1997;6:45–60. [PubMed: 26141962]
  • Green MJ, Biesecker BB, McInerney AM, et al. An interactive computer program can effectively educate patients about genetic testing for breast cancer susceptibility. American Journal of Medical Genetics. 2001;103:16–23. [PubMed: 11562929]
  • Green MJ, McInerney AM, Biesecker BB, Frost N. Education about genetic testing for breast cancer susceptibility: patient preferences for a computer program or genetic counsellor. American Journal of Medical Genetics. 2001;103:24–31. [PubMed: 11562930]
  • Gross E, Arnold N, Goette J, Schwartz-Boeger U, Kiechle M. A comparison of BRCA 1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet. 1999;105:72–8. [PubMed: 10480358]
  • Gui GP, Hogben RK, Walsh G, A'Hern R, Eeles R. The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography? European Journal of Cancer. 2001;37:1668–73. [PubMed: 11527694]
  • Hailey BJ, et al. Breast cancer attitudes, knowledge and screening behavior in women with and without a family history of breast cancer. HEALTH CARE WOMEN INT. 2000;21:701–15. [PubMed: 11813762]
  • Hallowell N. A qualitative study of the information needs of high-risk women undergoing prophylactic oophorectomy. Psycho-oncology. 2000;9(6):486–95. [PubMed: 11180583]
  • Hallowell N, Jacobs I, Richards M, Mackay J, Gore M. Surveillance or Surgery? A description of the factors that influence high risk premenopausal women’s decisions about prophylactic oophorectomy. Journal of Medical Genetics. 2001;38:683–91. [PMC free article: PMC1734749] [PubMed: 11594337]
  • Hallowell N, et al. Talking about chance: the presentation of risk information during genetic counselling for breast and ovarian cancer. Journal of Genetic Counselling. 1997;6:269–86. [PubMed: 26142235]
  • Hallowell N, et al. Recall of numerical risk estimates and counsellees’ perceptions of the importance of risk information following genetic counselling for beast and ovarian cancer. Psychology Health & Medicine. 1997;2:149–159.
  • Hallowell N, et al. Women’s need for information before attending genetic counselling for familial breast or ovarian cancer: a questionnaire, interview and observational study. British Medical Journal. 1997;314:281–283. [PMC free article: PMC2125728] [PubMed: 9022494]
  • Hallowell N. You don’t want to lose your ovaries because you think I might become a man. Women’s perceptions of prophylactic surgery as a cancer risk management option. Psycho-Oncology. 1998;7:263–75. [PubMed: 9638787]
  • Hallowell N, Murton F. The value of written summaries of genetic consultations. Patient Education and Counselling. 1998;35:27–34. [PubMed: 9832894]
  • Harper Report Working Group for the Chief Medical Officer. Genetics and cancer services: Report of a Working Group for the Chief Medical Officer, Department of Health. London: Department of Health; 1998.
  • Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. New England Journal of Medicine. 1999;340:77–84. [PubMed: 9887158]
  • Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. Journal of the National Cancer Institute. 2001;93:1633–7. [PubMed: 11698567]
  • Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obesity Reviews. 2003;4:157–173. [PubMed: 12916817]
  • Hatcher MB, Fallowfield L, A'Hern R. The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. British Medical Journal. 2001;322:76–9. [PMC free article: PMC26594] [PubMed: 11154619]
  • Hawley W, Nuovo J, DeNeef CP, Carter P. Do oral contraceptive agents affect the risk of breast cancer? A meta -analysis of the case-control reports. Journal of the American Board of Family Practice. 1993;6:123–35. [PubMed: 8452064]
  • Hershman, et al. Outcomes of Tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. Journal of Clinical Oncology. 2002;20:9–16. [PubMed: 11773148]
  • Hill ADK, Doyle JM, McDermott EW, O’Higgins NJ. Hereditary breast cancer. British Journal of Surgery. 1997;84(10):1334–1339. [PubMed: 9361585]
  • Hogervorst FB, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nature Genetics. 1995;10:208–12. [PubMed: 7663517]
  • Holleb AI, Montgomery R, Farrow JH. The hazard of incomplete simple mastectomy. Surgery, Gynecology & Obstetrics. 1965:819–22. [PubMed: 5838290]
  • Hopwood P, Keeling F, Long A, Pool C, Evans G, Howell A. Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. Psycho-oncology. 1998;7:402–412. [PubMed: 9809331]
  • Hopwood P, Lee A, Shenton A, Baildam A, Brain A, Lalloo F, et al. Clinical follow-up after bilateral risk reducing ('prophylactic') mastectomy: Mental health and body image outcomes. Psycho-Oncology. 2000;9:462–72. [PubMed: 11180581]
  • Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, et al. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA. 1995;273:577–85. [PubMed: 7837392]
  • Hou MF, Chuang HY, Ou-Yang F, Wang CY, Huang CL, Fan HM, et al. Comparison of breast mammography, sonography and physical examination for screening women at high risk of breast cancer in Taiwan. Ultrasound in Medicine & Biology. 2002;28:415–20. [PubMed: 12049952]
  • Houlston RS, et al. Family history and risk of breast cancer. Journal of Medical Genetics. 1992;29:154–7. [PMC free article: PMC1015888] [PubMed: 1552556]
  • Hughes C, Gomez-Caminero A, Benkendorf J, Kerner J, Isaacs C, Barter J, et al. Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. PATIENT EDUC COUNS. 1997;32:51–62. [PubMed: 9355572]
  • Husson G, Herrinton LJ. How accurately does the medical record capture maternal history of cancer? Cancer Epidemiology, Biomarkers & Prevention. 2000;9:765–8. [PubMed: 10919750]
  • Hyland F, Kinmonth AL, Marteau TM, Griffin S, Murrell P, Spiegelhalter D, et al. Raising concerns about family history of breast cancer in primary care consultations: prospective, population based study. Women's Concerns Study Group. BMJ. 2001;322:27–8. [PMC free article: PMC26605] [PubMed: 11141150]
  • IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet. 2002;360:817–24. [PubMed: 12243915]
  • International Agency for Research on Cancer (IARC). IARC Press; Lyon: Breast cancer screening. 2002
  • International Agency for Research on Cancer (IARC). IARC Press; Lyon: IARC Handbooks of Cancer Prevention: Volume 6: Weight Control and Physical Activity. 2002
  • Jacobsen PB, Valdimarsdottir HB, Brown KL, Offit K. Decision-making about genetic testing among women at familial risk for breast cancer. Psychosomatic Medicine. 1997;59:459–66. [PubMed: 9316177]
  • Josephson U, Wickman M, Sandelin K. Initial experiences of women from hereditary breast cancer families after bilateral prophylactic mastectomy: a retrospective study. European Journal of Surgical Oncology. 2000;26:351–6. [PubMed: 10873354]
  • Julian-Reynier C, Eisinger F, Chabal F, Lasset C, Nogues C, Stoppa-Lyonnet D, et al. Disclosure to the family of breast/ovarian cancer genetic test results: patient's willingness and associated factors. American Journal of Medical Genetics. 2000;94:13–8. [PubMed: 10982476]
  • Julian-Reynier C, Eisinger F, Chabal F, Aurran Y, Noguès C, Vennin P, Bignon Y-J, Machelard–Roumagnac M, Maugard-Louboutin C, Serin D, Versini S, Mercuri M, Sobol H. Cancer genetic clinics: target population and consultees’ expectations. European Journal of Cancer. 1996;32A:398–403. [PubMed: 8814681]
  • Julian-Reynier C, Welkenhuysen M, Hagoel L, et al. on behalf of the CRISCOM* Working Group Risk communication strategies: state of the art and effectiveness in the context of cancer genetics services. Eur J Human Genetics. 2003;11:725–36. [PubMed: 14512961]
  • Kauff ND, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine. 2002;346:1609–15. [PubMed: 12023992]
  • Kelly PT. Counselling needs of women with a maternal history of breast cancer. Patient Counselling and Health Education. 1980;2:118–124. [PubMed: 10249188]
  • Kelly PT. Informational needs of individuals and families with hereditary cancers. Seminars in Oncology Nursing. 1992;8:288–292. [PubMed: 1480860]
  • Kerlikowske K, Carney PA, Geller B, Mandelson MT, Taplin SH, et al. Performance of screening Mammography among Women with and without a First Degree Relative with Breast Cancer. Ann Intern Med. 2000;133:855–63. [PubMed: 11103055]
  • Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA. 1993;270:2444–50. (see comments) [PubMed: 8230621]
  • Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography.(comment). JAMA. 1996;276:33–8. [PubMed: 8667536]
  • Kerr B, Foulkes WD, Cade D, Hadfield L, Hopwood P, Serruya C, et al. False family history of breast cancer in the family cancer clinic. European Journal of Surgical Oncology. 1998;24:275–9. [PubMed: 9724992]
  • Khuder SA, et al. Smoking and breast cancer: a meta-analysis. Reviews on Environmental Health. 2001;16:253–61. [PubMed: 12041881]
  • King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251–6. [PubMed: 11710890]
  • Kinney AY, Croyle RT, Dudley WN, Bailey CA, Pelias MK, Neuhausen SL. Knowledge, attitudes, and interest in breast-ovarian cancer gene testing: a survey of a large African-American kindred with a BRCA1 mutation. Preventive Medicine. 2001;33:543–51. [PubMed: 11716649]
  • Klip H, Burger CW, Kenemans P, van Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes and Control. 2000;11:319–344. [PubMed: 10843444]
  • Kollias J, Sibberingg DM, Blamey RW, Holland PA, Obuszko Z, Wilson AR, et al. Screening women aged less than 50 years with a family history of breast cancer. European Journal of Cancer. 1998;34:878–83. [PubMed: 9797701]
  • Koster JP, Gotzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. The Cochrane Library. 2003;3:1–13. [PMC free article: PMC7387360] [PubMed: 12804462]
  • Kozlowski P, Krzyzosiak WJ. Combined SSCO/duplex analysis by capillary electrophoresis for more efficient mutation detection. Nucleic Acids Res. 2001;29:E71. [PMC free article: PMC55818] [PubMed: 11452040]
  • Kreuter MW. Dealing with competing and conflicting risks in cancer communication. Journal of the National Cancer Institute Monograph. 1999;25:27–35. [PubMed: 10854454]
  • Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology. 2000;215:267–79. [PubMed: 10751498]
  • Lalloo F, Boggis CR, Evans DG, Shenton A, Threlfall AG, Howell A. Screening by mammography, women with a family history of breast cancer. European Journal of Cancer. 1998;34:937–40. [PubMed: 9797712]
  • Lalloo F, Varley J, Ellis D, O’Dair L, Pharoah P, Evans DGR. the early onset breast cancer study Group. Family history is predictive of pathogenic mutations in BRCA1, BRCA2 and TP53 with high penetrancegg in a population based study of very early onset breast cancer. Lancet. 2003;361:1011–1012. [PubMed: 12672316]
  • Lancaster JM, et al. Dideoxy fingerprinting assay for BRCA1 mutation analysis. Molecular Carcinogenesis. 1997;19:176–9. [PubMed: 9254884]
  • Law J, Faulkner K. Cancers detected and induced and associated risk and benefit in a breast screening programme. British Journal of Radiology. 2001;74:1121–7. [PubMed: 11777770]
  • Law J. Cancers detected and induced in mammographic screening: new screening schedules and younger women with family history. British Journal of Radiology. 1997;70:62–9. [PubMed: 9059297]
  • Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutation of a mut S homolog in hereditary non polyposis colorectal cancer. Cell. 1993;75:1215–1225. [PubMed: 8261515]
  • Leggatt V, Mackay J, Marteau TM, Yates JR. The psychological impact of a cancer family history questionnaire completed in general practice. Journal of Medical Genetics. 2000;37:470–2. [PMC free article: PMC1734599] [PubMed: 10928860]
  • Leggatt V, Mackay J, Yates JR. Evaluation of questionnaire on cancer family history in identifying patients at increased genetic risk in general practice. BMJ. 1999;319:757–8. (see comments) [PMC free article: PMC28230] [PubMed: 10488003]
  • Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. Journal of Clinical Oncology. 1994;12:843–50. [PubMed: 8151327]
  • Lerman C, Hughes C, Lemon SJ, Main D, Snyder C, Durham C, et al. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. Journal of Clinical Oncology. 1998;16:1650–4. (see comments) [PubMed: 9586874]
  • Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA. 1996;275:1885–92. (see comments) [PubMed: 8648868]
  • Lerman C, Seay J, Balshem A, Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. American Journal of Medical Genetics. 1995;57:385–92. [PubMed: 7677139]
  • Lerman C, et al. The influence of psychological distress on use of genetic testing for cancer risk. Journal of Consulting & Clinical Psychology. 1997;65:414–20. [PubMed: 9170764]
  • Lindberg NM, Wellisch D. Anxiety and compliance among women at risk for breast cancer. Annals of Behavioral Medicine. 2001;23:298–303. [PubMed: 11761347]
  • Lipworth L, et al. History of breast-feeding in relation to breast cancer risk: a review of the epidemiologic literature. Journal of National Cancer Institute. 2000;92:302–12. [PubMed: 10675379]
  • Lloyd SM, Watson M, Oaker G, Sacks N, Della Rovere UQ, Gui G. Understanding the experience of prophylactic bilateral mastectomy: A qualitative study of ten women. Psycho-Oncology. 2000;9:473–85. [PubMed: 11180582]
  • Loader S, Levenkron JC, Rowley PT. Genetic testing for breast-ovarian cancer susceptibility: a regional trial. Genetic Testing. 1998;2:305–13. [PubMed: 10464609]
  • Lodder L, Frets PG, Trijsburg RW, Tibben A, Meijers-Heijboer EJ, Duivenvoorden HJ, et al. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing. European Journal of Human Genetics. 2001;9:492–500. [PubMed: 11464240]
  • Lodder LN, Frets PG, Trijsberg RW, Meijers-Heijboer EJ, et al. Presymptomatic testing for BRCA1 and BRCA2: how distressing are the pre-test weeks? J Med Genet. 1999;36:906–13. [PMC free article: PMC1734277] [PubMed: 10593998]
  • Longnecker MP. Alcohol beverage consumption in relation to risk of breast cancer: meta-analysis and review. Cancer Causes & Control. 1994;5:73–82. [PubMed: 8123780]
  • Longnecker MP, et al. A meta-analysis of alcohol consumption in relation to risk of breast cancer. JAMA. 1988;260:652–6. [PubMed: 3392790]
  • Lynch HT, Lemon SJ, Durham C, Tinley ST, Connolly C, Lynch JF, et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 1997;79:2219–28. (see comments) [PubMed: 9179070]
  • Macmillan RD. Screening women with a family history of breast cancer--results from the British Familial Breast Cancer Group. European Journal of Surgical Oncology. 2000;26:149–52. [PubMed: 10744933]
  • Malkin D, Li FP, Strong LC, et al. Germline TP53 mutations in cancer families. Science. 1990;250:1233–1238. [PubMed: 1978757]
  • Marchbanks PA, et al. Oral contraceptives and the risk of breast cancer. New England Journal of Medicine. 2002;346:2025–32. [PubMed: 12087137]
  • Markoff A, et al. Comparison of conformation-sensitive gel electrophoresis and single-strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols. EUR J HUM GENET. 1998;6:145–50. [PubMed: 9781059]
  • McAllister M, O’Malley K, Hopwood P, et al. Management of women with a family history of breast cancer in the North West Region: training for implementing a vision of the future. J Med Genet. 2002;39:531–535. [PMC free article: PMC1735171] [PubMed: 12114490]
  • McCaul KD, Branstetter AD, Schroeder DM, Glasgow RE. What is the relationship between breast cancer risk and mammography screening? A meta-analytic review. Health Psychology. 1996;15:423–9. [PubMed: 8973921]
  • McPherson K, Steel CM, Dixon JM. Breast cancer – epidemiology, risk factors, and genetics. BMJ. 2000;321:624–628. [PMC free article: PMC1118507] [PubMed: 10977847]
  • McTiernan A, Gilligan MA, Redmond C. Assessing individual risk for breast cancer: risky business. (Review) (60 refs). Journal of Clinical Epidemiology. 1997;50:547–56. [PubMed: 9180647]
  • McTiernan A, Kuniyuki A, Yasui Y, Bowen D, Burke W, Culver JB, et al. Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiology, Biomarkers & Prevention. 2001;10:333–8. [PubMed: 11319173]
  • Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000;355:2015–20. (see comments) [PubMed: 10885351]
  • Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000;355:2015–20. (see comments) [PubMed: 10885351]
  • Meijers-Heijboer H, van Geel B, van Putten WLJ, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MBE, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. New England Journal of Medicine. 2001;345:159–64. [PubMed: 11463009]
  • Meiser B, Butow P, Barratt A, Friedlander M, Gattas M, Kirk J, et al. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecologic Oncology. 1999;75:122–9. [PubMed: 10502438]
  • Meiser B, Butow P, Barratt A, Friedlander M, Kirk J, Gaff C, et al. Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer. Breast Cancer Research & Treatment. 2000;59:101–11. [PubMed: 10817345]
  • Meiser B, Butow P, Friedlander M, Barratt A, Schnieden V, Watson M, et al. Psychological impact of genetic testing in women from high-risk breast cancer families. European Journal of Cancer. 2002;38:2025–31. [PubMed: 12376208]
  • Meiser B, Tiller K, et al. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer. Psycho-oncology. 2000;9(6):496–503. [PubMed: 11180584]
  • Meiser B, Halliday JL. What is the impact of genetic counselling in women at increased risk of developing hereditary breast cancer? A meta-analytic review. Social Science & Medicine. 2002;54:1463–70. [PubMed: 12061481]
  • Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. The Lancet. 2003;362:419–27. [PubMed: 12927427]
  • Moller P, Borg A, Evans DG, Haites N, et al. Survival in prospectively ascertained familial breast cancer: Analysis of a series of stratified by tumour characteristics, BRCA mutations and oophorectomy. International-Journal-of-Cancer. 2002;101:555–9. [PubMed: 12237897]
  • Montagna M, Santacatterina M, Torri A, Menin C, Zullato D, Chieco-Bianchi L. Identification of a 3kb Alu-mediated BRCA 1 gene rearrangement in two breast/ovarian cancer families. Oncogene. 1999;18:4160–5. [PubMed: 10435598]
  • Mueller C, Haworth A. Draft best practice guidelines for molecular analysis of hereditary breast and ovarian cancer, European Molecular Genetics Quality Network. 2001. [accessed 18.3.03]. http://www​.emqn.org/guidelines/brca_eu​.php.
  • Murday V. Genetic counselling in the cancer family clinic. European Journal of Cancer. 1994;30A:2012–5. [PubMed: 7734215]
  • Myles J, Duffy S, Nixon R, Boggis C, Howell A, Shenton A, et al. Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk. Revue d Epidemiologie et de Sante Publique. 2001;49:471–5. [PubMed: 11845096]
  • Nagata C, et al. Effects of menstrual and reproductive factors on the risk of breast cancer: meta-analysis of the case control studies in Japan. Japanese Journal of Cancer Research. 1995;86:910–5. [PMC free article: PMC5920604] [PubMed: 7493908]
  • Narod SA, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet. 2000;356:1876–81. [PubMed: 11130383]
  • Narod SA, et al. Oral Contraceptives and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2002;94:1773–9. [PubMed: 12464649]
  • National Surgical Adjuvant Breast and Bowel Project. NSABP Protocol P-1: a clinical trial to determine the worth of tamoxifen for preventing breast cancer. Pittsburgh, PA: NSABP; 1992.
  • Negri E, et al. Risk factors for breast cancer: pooled results from three Italian case-control studies. American Journal of Epidemiology. 1988;128:1207–15. [PubMed: 3195562]
  • Nelen MR, Padberg GW, Peeters EAJ, et al. Localisation of the gene for Cowden disease to chromosome lOq22–23. Nature Genet. 1996;13:114–116. [PubMed: 8673088]
  • Newman B, Austin MA, Lee M, King M. Inheritance of human breast cancer: Evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci. 1988;85:3044–3048. [PMC free article: PMC280139] [PubMed: 3362861]
  • National Health Service Breast Screening Programme (NHSBSP). Review of Radiation Risk in Breast Screening: Report by a joint working party of the NHSBSP National Coordinating Group for Physics Quality Assurance and the National Radiological Protection Board. NHSBSP Publication No 54. Sheffield: NHS Cancer Screening Programmes; 2003.
  • NHS Cancer Screening Programmes and Cancer Research Campaign. Familial Breast and Ovarian Cancer: an information pack for primary care. London: Department of Health; 2001.
  • NICE Guideline Development Process Manuals. London: National Institute for Clinical Excellence;
    Guideline Development Process - Information for National Collaborating Centres and Guideline Development Groups. 2001.
    Guideline development Process - Information for Stakeholders. 2002.
    Guideline Development Process - Information for the Public and the NHS. 2001.
  • Nicolaides NC, Papadopoulos N, Liu B, et al. Mutation of two PMS homologs in hereditary non polyposis colorectal cancer. Nature. 1994;371:75–80. [PubMed: 8072530]
  • Nixon RM, Pharoah P, Tabar L, Krusemo UB, Duffy SW, Prevost TC, et al. Mammographic screening in women with a family history of breast cancer: some results from the Swedish two-county trial. Revue d Epidemiologie et de Sante Publique. 2000;48:325–31. [PubMed: 11011299]
  • Noorani HZ, McGahan L. Predictive genetic testing for breast and prostate cancer. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de 'Evaluation des Technologies de la Sante. Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1999. 1895561698. Technology Report Is. 85. 1999. Ref Type: Report.
  • O’Driscoll D, Warren R, Mackay J, Britton P, Day NE. Screening with breast ultrasound in a population at moderate risk due to family history. J Med Screen. 2001;8:106–9. [PubMed: 11480440]
  • Office for National Statistics. Breast cancer: incidence rate rises while death rate falls. 2003. [accessed 5 December 2003]. http://www​.statistics​.gov.uk/cci/nugget.asp?id=575. released 31 October 2003 at 9.30am.
  • Office for National Statistics. Cancer trends in England and Wales, 1950–1999, Studies on Medical and Population Subjects No 66. London: The Stationery Office; 2001.
  • Ottman R, et al. Practical guide for estimating risk for familial breast cancer. Lancet. 1983;2:556–8. [PubMed: 6136703]
  • Palmer JR, Rosenberg L. Cigarette smoking and the risk of breast cancer. Epidemiologic Reviews. 1993;15:145–56. [PubMed: 8405197]
  • Papadopoulos N, Nicolaides NC, Wei Y-F, et al. Mutation of a Mut L homolog in hereditary colon cancer. Science. 1994;263:1625–1629. [PubMed: 8128251]
  • Parent ME, Ghadirian P, Lacroix A, Perret C. The reliability of recollections of family history: implications for the medical provider. Journal of Cancer Education. 1997;12:114–20. [PubMed: 9229275]
  • Patenaude AF, et al. Acceptance of invitations for p53 and BRCA1 predisposition testing: factors influencing potential utilization of cancer genetic testing. Psyco-Oncology. 1996;5:241–50.
  • Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plastic Surgery. 1989;13:15–21. [PubMed: 2728994]
  • Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet. 2000;26:411–4. [PubMed: 11101836]
  • Pharoah PDP, Day NE, Duffy S, Easton DF, Ponder BAJ. Family history and the risk of breast cancer: a systematic review and meta-analysis. International Journal of Cancer. 1997;71:800–809. [PubMed: 9180149]
  • Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352:98–101. (see comments) [PubMed: 9672274]
  • Qureshi N, et al. A randomized controlled trial to assess the psychological impact of a family history screening questionnaire in general practice. Fam Pract. 2001;18:78–83. [PubMed: 11145633]
  • R&D Office of the Anglia & Oxford NHS Executive and the Unit for Public Health Genetics, Cambridge. Report of consensus meeting on the management of women with a family history of breast cancer. 1998. [Accessed 2002]. http://www​.medinfo.cam​.ac.uk/phgu/info_database​/public_documents/breastcaconsen​.asp.
  • Rebbeck TR, Levin MA, Eisen A, et al. Breast cancer risk after bilateral prophylatic oophorectomy in BRCA1 mutation carriers. Journal of the National Cancer Institute. 1999;91:1475–9. [PubMed: 10469748]
  • Rebbeck TR, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New England Journal of Medicine. 2002;346:1616–22. [PubMed: 12023993]
  • Rees, Bath Meeting the information needs of adult duaghters of women with early breast cancer. Cancer Nursing. 2000;23:71–79. [PubMed: 10673810]
  • Reichelt JG, Dahl AA, Heimdal K, Moller P. Uptake of genetic testing and pre-test levels of mental distress in Norwegian families with known BRCA1 mutations. Disease Markers. 1999;15:139–43. [PMC free article: PMC3850804] [PubMed: 10595268]
  • Richards CS, Ward PA, Roa BB, Friedman LC, Boyd AA, Kuenzli G, et al. Screening for 185delAG in the Ashkenazim. American Journal of Human Genetics. 1997;60:1085–98. [PMC free article: PMC1712425] [PubMed: 9150156]
  • Richards MPM, Hallowell N, Green JM, Murton F, Statham H. Counselling families with hereditary breast and ovarian cancer: A psychosocial perspective. J Genet Counsel. 1995;4:219–233. [PubMed: 24234371]
  • Richards MPM, Hallowell N, Green JM, et al. Counselling families with hereditary breast and ovarian cancer: a psychosocial perspective. J Genet Couns. 1995;4:219–33. [PubMed: 24234371]
  • Richards MPM. Genetic counselling for those with a family history of breast or ovarian cancer. Acta Oncologica. 1999;3:559–565. [PubMed: 10427943]
  • Richter S, et al. One step direct detection of recurrent mutations in the breast cancer susceptibility gene, BRCA1. Int J Oncol. 1998;12:1263–7. [PubMed: 9592184]
  • Robinson MD, Chu CE, Turner G, Bishop DT, Taylor GR. Exon deletions and duplications in BRCA 1 detected by semiquantitative PCR. Genet Test. 2000;4:49–54. [PubMed: 10794361]
  • Romieu I, et al. Oral contraceptives and breast cancer: review and meta-analysis. Cancer. 1990;66:2253–63. [PubMed: 2147122]
  • Rozycka M, Collins N, Stratton MR, Wooster R. Rapid detection of DNA sequence variants by conformation-sensitive capillary electrophoresis. Genomics. 2000;70:34–40. [PubMed: 11087659]
  • Rushton L, Jones DR. Oral contraceptive use and breast cancer risk: A meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use. British Journal of Obstetrics and Gynaecology. 1992;99:239–46. [PubMed: 1534994]
  • Sachs L, Taube A, Tishelman C. Risk in numbers--difficulties in the transformation of genetic knowledge from research to people--the case of hereditary cancer. Acta Oncologica. 2001;40:445–53. [PubMed: 11504302]
  • Sætersdal A, Dorum A, Heimdal K, Helgerud P, Sager EM, Bohler P, et al. Inherited predisposition to breast carcinoma. Results of first round examination of 537 women at risk. Anticancer Research. 1996;16:1989–92. [PubMed: 8712731]
  • Schairer C, Lubin J, Troisi R, et al. Menopausal oestrogen and oestrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283:485–491. [PubMed: 10659874]
  • Schapira MM, Nattinger AB, McHorney CA. Frequency or probability? A qualitative study of risk communication formats used in health care. Medical Decision Making. 2001;21(6):459–67. 459–67. Nov–Dec.(59 ref) [PubMed: 11760103]
  • Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of Clinical Oncology. 2002;20:1260–8. (see comments) [PubMed: 11870168]
  • Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Journal of Obstetrics and Gyanecology. 1995;85:793–801. [PubMed: 7724116]
  • Schrag D, et al. Decision analysis - effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. New England Journal of Medicine. 1997;336:1465–71. [PubMed: 9148160]
  • Schwartz MD, Benkendorf J, Lerman C, et al. Impact of educational print materials on knowledge, attitudes and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women. Cancer. 2001;92:932–940. [PubMed: 11550168]
  • Schwartz MD, Rimer BK, Daly M, et al. A randomized trial of breast cancer risk counseling: the impact on self-reported mammography use. American Journal of Public Health. 1999;89:924–6. [PMC free article: PMC1508646] [PubMed: 10358689]
  • Schwartz MD, et al. Distress, personality, and mammography utilization among women with a family history of breast cancer. Health Psychology. 1999;18:327–32. [PubMed: 10431933]
  • Sellers TA, Mink PJ, Cerham JR, Zheng W, Anderson KE, Kushi LH, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Annals of Internal Medicine. 1997;127:973–80. [PubMed: 9412302]
  • Sevilla C, Moatti JP, Julian-Reynier C, Eisinger F, Stoppa-Lyonnet D, Bressac-de Paillerets B, Sobol H. Testing for BRCA1 mutations: a cost effectiveness analysis. European Journal of Human Genetics. 2002;10:599–606. [PubMed: 12357330]
  • Shah S, Evans DGR, Blair V, et al. Assessment of relative risk of second primary tumours after ovarian cancer and the usefulness of double primary cases as a source if material for genetic studies with a cancer registry. Cancer. 1993;72:819–827. [PubMed: 8334636]
  • Shiloh S, et al. Motivations, perceptions and interpersonal differences associated with interest in genetic testing for breast cancer susceptibility among women at high and average risk. Psychology and Health. 1998;13:1071–86.
  • Sillero-Arenas M, et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstetrics & Gynecology. 1992;79:286–94. [PubMed: 1530988]
  • Smith K, West J, Croyle R, Botkin J. Familial context of genetic testing for cancer susceptibility; moderating effect of siblings’ test result on psychological distress one to two weeks after BRCA1 mutation testing. Cancer, Epidemiology, Biomarkers & Prevention. 1999;8:385–392. [PubMed: 10207644]
  • Smith-Warner SA, Spiegelman D, Yaun SS, van den Brandt PA, Folsom AR, Goldbohm RA, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 1998;279:535–40. (see comments) [PubMed: 9480365]
  • Stefanek ME, Helzlsouer KJ, Wilcox PM, Houn F. Predictors of and Satisfaction with Bilateral Prophylactic Mastectomy. Preventive Medicine. 1995;24:412–9. [PubMed: 7479633]
  • Steinberg J, Goodwin PJ. Alcohol and breast cancer risk - putting the current controversy into perspective. Breast Cancer Research & Treatment. 1991;19:221–31. [PubMed: 1838016]
  • Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265:1985–90. (see comments) (erratum appears in JAMA 1991 Sep 11;266(10):1362) [PubMed: 1826136]
  • Stoutjesdijk MJ, Boetes C, Jager GJ, Beex L, Bult P, Hendriks JH, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer.(comment). Journal of the National Cancer Institute. 2001;93:1095–102. [PubMed: 11459871]
  • Stratton JF, Thompson D, Bobrow L, et al. The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet. 1999;65:1725–32. [PMC free article: PMC1288384] [PubMed: 10577927]
  • Stratton JF, Pharoah P, Smith SK, Easton D, Ponder B. A systematic review and meta-analysis of family history and risk of ovarian cancer. British Journal of Obstetrics and Gynaecology. 1998;105:493–9. [PubMed: 9637117]
  • Struewing JP, Lerman C, Kase RG, Giambarresi TR, Tucker MA. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiology, Biomarkers & Prevention. 1995;4:169–73. [PubMed: 7742725]
  • Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Journal of the National Cancer Institute Monographs. 1995:33–5. [PubMed: 8573450]
  • Sutcliffe S, Pharoah PDP, Easton DF, et al. UKCCCR Familial Ovarian Cancer Study Group. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer. Int J Cancer. 2000;87:110–117. [PubMed: 10861460]
  • Tabar L, Yen MF, Vitak B, et al. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003;361:1405–10. [PubMed: 12727392]
  • Taplin S, et al. Revisions in the risk-based breast cancer screening program at Group Health Cooperative. Cancer. 1990;66:812–18. [PubMed: 2386908]
  • Tengs T, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: A decision analysis. Medical Decision Making. 1998;18(4):365–75. [PubMed: 10372578]
  • Tengs TO, Berry DA. The cost effectiveness of testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Disease Management and Clinical Outcome. 2000;1:15–24.
  • Tercyak K, Lerman C, Peshkin B, et al. Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counselling and testing for breast and ovarian cancer risk. Health Psychology. 2001;20:217–22. [PubMed: 11403219]
  • Terry PD, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: along latency period? International Journal of Cancer. 2002;100:723–8. [PubMed: 12209614]
  • Theis B, Boyd N, Lockwood G, Tritchler D. Accuracy of family cancer history in breast cancer patients. European Journal of Cancer Prevention. 1994;3:321–7. [PubMed: 7950886]
  • Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, Oudkerk M. Earlier detection of breast cancer by surveillance of women at familial risk. European Journal of Cancer. 2000;36:514–9. [PubMed: 10717529]
  • Tilanus-Linthorst MM, Obdeijn IM, Bartels KC, de Koning HJ, Oudkerk M. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Research & Treatment. 2000;63:53–60. [PubMed: 11079159]
  • Tiller K, Meiser B, Butow P, et al. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer. Gynecol Oncol. 2002;86(2):212–9. [PubMed: 12144830]
  • Tischkowitz M, Wheeler D, France E, Chapman C, Lucassen A, Sampson J, et al. A comparison of methods currently used in clinical practice to estimate familial breast cancer risks. Annals of Oncology. 2000;11:451–4. [PubMed: 10847465]
  • Unger MA, Nathanson KL, Calzone K, Antin-Ozerkis D, Shih HA, Martin AM, et al. Screening for genomic rearrangements in families with breat and ovarian cancer identifies BRCA 1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2003;67:841–50. [PMC free article: PMC1287889] [PubMed: 10978226]
  • Ursin G, Tseng CC, Paganini-Hill A, Enger S, Wan PC, Formenti S, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? Journal of Clinical Oncology. 2002;20:699–706. (see comments) [PubMed: 11821451]
  • Vachon CM, et al. Investigation of an interaction of alcohol intake and family history on breast cancer risk in Minnesota breast cancer family study. Cancer. 2001;92:240–8. [PubMed: 11466675]
  • Van Hoften C, Burger H, Peeters PHM, Grobbee DE, Van Noord PAH, Leufkens HGM. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: The DOM cohort. Int J Cancer. 2000;87:591–4. [PubMed: 10918202]
  • Van Roosmale MS, et al. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. Journal of Clinical Oncology. 2002;20:2092–100. [PubMed: 11956270]
  • van Zuuren FJ, van Schie ECM, van Baaren NK. Uncertainty in the information provided during genetic counselling. Patient Education and Counselling. 1997;32:129–139. [PubMed: 9355580]
  • Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women... including commentary by Pritchard KI. Lancet. 1998 1998 1980 Jul 11;352352(9122):93–7. 80–1, 93–7. [PubMed: 9672273]
  • Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet. 2002;359:1122–4. [PubMed: 11943263]
  • Wagner T, Stoppa-Lyonnet D, Fleischmann E, Muir D, Pages S, Sandberg T, et al. Denaturing high-performance liquid chromatography detects relability BRCA 1 and BRCA 2 mutations. Genomics. 1999;62:369–76. [PubMed: 10644434]
  • Wagner TM, Moslinger R, Langbauer G, Ahner R, Fleischmann E, Auterith A, et al. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. British Journal of Cancer. 2000;82:1249–53. [PMC free article: PMC2374490] [PubMed: 10755396]
  • Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe MJ, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.(comment). Journal of Clinical Oncology. 2001;19:3524–31. [PubMed: 11481359]
  • Watson E, Clements A, Lucassen P, et al. Education improves general practitioner (GP) management of familial breast/ovarian cancer: findings from a cluster randomised controlled trial (Letter). Journal of Medical Genetics. 2002;39:779–781. [PMC free article: PMC1734993] [PubMed: 12362040]
  • Watson E, Clements A, Yudkin P, et al. Evaluation of the impact of two educational interventions on GP management of familial breast/ovarian cancer cases: a cluster randomised controlled trial. British Journal of General Practice. 2001;51:817–821. [PMC free article: PMC1314127] [PubMed: 11677705]
  • Watson M, et al. Psychological impact of testing (by linkage) for the BRCA1 breast cancer gene: an investigation of two families in the research setting. Psycho-Oncology. 1996;5:233–9.
  • Watson M, Duvivier V, Wade Walsh M, Ashley S, Davidson J, Papaikonomou M, Murday V, Sacks N, Eeles R. Family history of breast cancer: what do women understand and recall about their risk? Journal of Medical Genetics. 1998;35:731–738. [PMC free article: PMC1051425] [PubMed: 9733031]
  • Watson M, Lloyd S, Davidson J, Meyer L, Eeles R, Ebbs S, Murday V. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. British Journal of Cancer. 1999;79:868–874. [PMC free article: PMC2362694] [PubMed: 10070883]
  • Werness BA, Ramus SJ, Whittemore AS, et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol. 2000;31:1420–4. [PubMed: 11112219]
  • Willemsen HW, Kaas R, Peterse JH, Rutgers EJT. Breast carcinoma in residual breast tissue after prophylactic bilateral subcutaneous mastectomy. European Journal of Surgical Oncology. 1998;24:331–2. [PubMed: 9725003]
  • Winter PR, Wiesner GL, Finnegan J, Bartels D, LeRoy B, Chen PL, et al. Notification of a family history of breast cancer: issues of privacy and confidentiality. American Journal of Medical Genetics. 1996;66:1–6. [PubMed: 8957501]
  • Ziegler LD, Kroll SS. Primary Breast-Cancer After Prophylactic Mastectomy. American Journal of Clinical Oncology-Cancer Clinical Trials. 1991;14:451–4. [PubMed: 1951182]
Copyright © 2004, School of Health and Related Research (ScHARR), University of Sheffield.
Bookshelf ID: NBK65453
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (7.0M)

Other titles in this collection

Related NICE guidance and evidence

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...